Clinical Trials Logo

Angiomyolipoma clinical trials

View clinical trials related to Angiomyolipoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02654340 Terminated - Clinical trials for Lymphangioleiomyomatosis

Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)

TuScCom
Start date: August 1, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s

NCT ID: NCT02539459 Terminated - Clinical trials for Sporadic Angiomyolipomas (AMLs)

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

SAGE
Start date: September 23, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.